Literature DB >> 18652006

Abnormal myocardial flow reserve in sickle cell disease: a myocardial contrast echocardiography study.

Ana G Almeida1, Francisco Araújo, Fernanda Rego, Cláudio David, Mário G Lopes, J Ducla-Soares.   

Abstract

BACKGROUND: Sickle cell disease (SCD) is characterized by obstruction of microvessels leading to ischemia and necrosis. We have aimed to demonstrate whether myocardial contrast echocardiography (MCE) is able to detect myocardial perfusion abnormalities in SCD patients and to assess their relationship with left ventricle (LV) perfusion and systolic function.
METHODS: A group of 25 patients with SCD and a control group of 19 normal individuals were studied. Using MCE, myocardial perfusion reserve indices (A, beta, and A x beta) were obtained, before and after hyperemia with dypiridamole. LV function was also analyzed: ejection fraction (EF), index of myocardial performance (IMP), the ratio of transmitral early-diastolic flow velocity E and the pulsed tissue Doppler mitral annular early diastolic velocity Ea (E/Ea) (E/Ea), tissue Doppler mitral annular peak systolic velocity (Sa), and peak systolic strain (S) were obtained.
RESULTS: Myocardial velocity (beta) and myocardial blood flow (A x beta) reserves were lower in the patients than in controls (1.7 +/- 0.4 vs. 3.3 +/- 0.2, P = 0.000 and 2.1 +/- 0.6 vs. 4.1 +/- 0.2, P = 0.000, respectively). In SCD patients, a correlation was found between beta reserve and EF, IMP, Sa, E/Ea, and S% and between A x beta reserve and Sa.
CONCLUSIONS: MCE detected abnormal perfusion reserve in patients with SCD, which correlated with systolic function indices. This suggests that perfusion plays a role in SCD ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652006     DOI: 10.1111/j.1540-8175.2008.00666.x

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  6 in total

1.  Skeletal and myocardial microvascular blood flow in hydroxycarbamide-treated patients with sickle cell disease.

Authors:  Vandana Sachdev; Stanislav Sidenko; Melinda D Wu; Caterina P Minniti; Hwaida Hannoush; Cynthia L Brenneman; Myron A Waclawiw; Andrew E Arai; Alan N Schechter; Gregory J Kato; Jonathan R Lindner
Journal:  Br J Haematol       Date:  2017-09-07       Impact factor: 6.998

Review 2.  Myocardial infarction in sickle cell disease: use of translational imaging to diagnose an under-recognized problem.

Authors:  Paul Chacko; Eric H Kraut; Jay Zweier; Charles Hitchcock; Subha V Raman
Journal:  J Cardiovasc Transl Res       Date:  2012-11-21       Impact factor: 4.132

3.  Sickle cell disease and ventricular myocardial strain: A systematic review.

Authors:  Nicholas S Whipple; Vijaya M Joshi; Ronak J Naik; Tisha Mentnech; Mary M McFarland; Vikki G Nolan; Jane S Hankins
Journal:  Pediatr Blood Cancer       Date:  2021-03-19       Impact factor: 3.838

Review 4.  Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters.

Authors:  Carlo Dal Lin; Francesco Tona; Elena Osto
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

5.  Subclinical Cardiac Dysfunction Is Associated With Extracardiac Organ Damages.

Authors:  Aymeric Menet; Brigitte Ranque; Ibrahima Bara Diop; Samuel Kingue; Roland N'guetta; Mamadou Diarra; Dapa Diallo; Saliou Diop; Ibrahima Diagne; Ibrahima Sanogo; David Chelo; Guillaume Wamba; Indou Deme-Ly; Blaise Felix Faye; Moussa Seck; Aissata Tolo; Kouakou Boidy; Gustave Koffi; Eli Cochise Abough; Cheick Oumar Diakite; Youssouf Traore; Gaëlle Legueun; Ismael Kamara; Lucile Offredo; Sylvestre Marechaux; Mariana Mirabel; Xavier Jouven
Journal:  Front Med (Lausanne)       Date:  2018-11-20

6.  Coronary microvascular dysfunction is associated with degree of anaemia in end-stage renal disease.

Authors:  Ashwin Radhakrishnan; Luke C Pickup; Anna M Price; Jonathan P Law; Kirsty C McGee; Larissa Fabritz; Roxy Senior; Richard P Steeds; Charles J Ferro; Jonathan N Townend
Journal:  BMC Cardiovasc Disord       Date:  2021-04-26       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.